文献速递血栓与止血

氨苯砜治疗122例免疫性血小板减少症患者的回顾性分析:疗效、安全性及与治疗反应相关的因素

A retrospective analysis of 122 immune thrombocytopenia patients treated with dapsone: Efficacy, safety and factors associated with treatment response.
PubMed 文献 · J Thromb Haemost · 2021-08-09

该回顾性研究纳入122例免疫性血小板减少症(ITP)患者,接受氨苯砜中位治疗6个月、中位随访3.4年。总缓解率66%(完全缓解24%),持续缓解率51%,81%的缓解者停药后中位维持26个月。不良反应发生率16%,11%因不良反应中断治疗,主要为溶血性贫血和高铁血红蛋白血症。

要点

  • 氨苯砜二线治疗ITP总缓解率66%,完全缓解率24%,持续缓解率51%。
  • 81%的缓解者停药后中位维持缓解26个月。
  • 16%出现不良反应,11%因不良反应停药,主要为溶血性贫血和高铁血红蛋白血症。

核心结论

  • 氨苯砜治疗ITP具有足够的疗效且耐受性良好。
  • 缓解者血红蛋白下降幅度显著大于非缓解者,提示阻断网状内皮系统可能参与其治疗作用。

研究设计与样本

  • 单中心回顾性研究,纳入122例ITP患者。
  • 氨苯砜中位治疗 duration 6个月,中位随访3.4年。

主要发现

  • 总缓解率66%,其中完全缓解24%。
  • 缓解者中24%在治疗期间复发,持续缓解率为51%。
  • 81%的缓解者停药后维持缓解,中位时间26个月。
  • 不良反应发生率16%,11%因不良反应中断治疗,主要原因为溶血性贫血和高铁血红蛋白血症。

临床怎么用

  • 氨苯砜可作为ITP的二线治疗选择,需监测血红蛋白下降及溶血性贫血、高铁血红蛋白血症等不良反应。

局限性

  • 回顾性研究设计。
  • 单中心经验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimum second-line treatment or best sequence of treatments for immune thrombocytopenia (ITP) are yet to be determined. Our institution has accumulated extensive experience regarding the use of dapsone as second-line therapy for ITP. OBJECTIVES: We aimed to assess the efficacy rate and safety of dapsone treatment in ITP patients. PATIENTS/METHODS: Here we report our experience in a retrospective study, including 122 patients, with a median treatment duration with dapsone of 6 months and a median follow-up period of 3.4 years. RESULTS: The overall response rate in this cohort was 66%, including 24% of complete responses. Among responders, in 24% a relapse occurred while on treatment. Therefore, a sustained response was observed in 51% of patients. Interestingly, 81% of the responders maintained the response after the interruption of treatment, for a median time of 26 months. Side effects were reported in 16% of the patients in this cohort and treatment was interrupted due to side effects in 11% of patients. The main cause in these cases was hemolytic anemia and methemoglobinemia. Reductions in hemoglobin levels during the use of dapsone were seen in 94% of the patients. Responders presented significantly greater reductions in their hemoglobin levels than nonresponders did: median hemoglobin drop of 1.9 g/dl vs. 1.2 g/dl (p = .004). CONCLUSIONS: Our findings suggest that dapsone has adequate efficacy and is well tolerated. Although the mechanism of action is still unclear, our observation that the degree in the drop of hemoglobin is greater in responders suggest a possible role of the blockage of the reticuloendothelial system in the therapeutic effect of the drug.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Colella MP, Orsi FA, Alves ECF, et al. A retrospective analysis of 122 immune thrombocytopenia patients treated with dapsone: Efficacy, safety and factors associated with treatment response. J Thromb Haemost. 2021. PMID: 34018665. doi:10.1111/jth.15396

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。